10月8日，Pacira BioSciences盘前飙涨逾44%，制药公司Viatris宣布，将以16.5亿美元的全现金交易收购Pacira BioSciences。收购价格为每股36.5美元，较Pacira前一交易日收盘价溢价44.8%。Pacira的非阿片类止痛药物Exparel和Zilretta在2025年的销售额分别为5.751亿美元和1.166亿美元。Exparel用于术后急性疼痛管理，而Zilretta则用于治疗膝关节骨关节炎引起的疼痛。
10月8日，Pacira BioSciences盘前飙涨逾44%，制药公司Viatris宣布，将以16.5亿美元的全现金交易收购Pacira BioSciences。收购价格为每股36.5美元，较Pacira前一交易日收盘价溢价44.8%。Pacira的非阿片类止痛药物Exparel和Zilretta在2025年的销售额分别为5.751亿美元和1.166亿美元。Exparel用于术后急性疼痛管理，而Zilretta则用于治疗膝关节骨关节炎引起的疼痛。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
